← Back to screener

Fulcrum Therapeutics, Inc. FULC

Rank #1513 · Nasdaq · $0.2B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
47.1
P/E
-25.4
P/B
1.05
ROE
-4.1%
Op. Margin
-27.4%
Debt Ratio
8%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★★☆☆
Average

P/E -25.4x, P/B 1.05x. Ranks in the top 46% of the universe.

Profitability ★☆☆☆☆
Weak

ROE -4.1%. Ranks in the top 78% of the universe.

Safety ★★★★★
Excellent

Debt ratio 8%. Ranks in the top 9% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★★
Excellent

Revenue growth of 2752.0% year over year. Ranks in the top 0% of the universe.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2019–$-0.0B$-0.0B$-0.0B–-29
2020$0.0B$-0.1B$-0.1B$-0.1B-954.5-37
2021$0.0B$-0.1B$-0.1B$0.1B-811.639
2022$0.0B$-0.1B$-0.1B$0.1B-423.025
2023$0.0B$-0.1B$-0.1B$0.2B-1774.913
2024$0.0B$-0.1B$-0.1B$0.2B-3945.211
2025$0.1B$-0.0B$-0.0B$0.2B-27.48

← See the full screener